Akorn announces FDA approvals

BUFFALO GROVE -- Akorn-Strides recently announced the approvals of two FDA applications for Ondansetron Injection USP single- and multiple-dose vials. Akorn-Strides is a joint venture that was formed in 2005 by Akorn Inc. and Strides Arcolab Limited. The primary mission for the joint venture is developing generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and central nervous system medicines.